Pharma BD Deal Intelligence
Novartis licensed ex-China rights to BeiGene's tislelizumab in a $650M-upfront, up-to-$2.2B deal, then walked away in 2023 as the PD-1 landscape shifted. BeiGene relaunched it solo as Tevimbra, winning FDA approvals in ESCC, gastric/GEJ, and first-line PD-L1-positive ESCC—vindicating the exit thesis and turning the reclaimed asset into a standalone global franchise.
BeiGene and Novartis announced a collaboration and license agreement for the development, manufacturing and commercialization of tislelizumab, BeiGene's…
In January 2021, BeiGene entered into a collaboration and license agreement with Novartis for the development, manufacturing and commercialization of…
BeiGene, Ltd. completed its corporate redomiciliation from the Cayman Islands to Switzerland and renamed to BeOne Medicines Ltd., effective May 27,…
Source summaries from our enrichment pipeline; follow links for originals.
All 19 sources with sentiment breakdown →
Novartis obtained ex-China development and commercialization rights to tislelizumab, BeiGene's anti-PD-1 monoclonal antibody, for $650 million upfront plus up to $1.55 billion in regulatory and sales milestones. BeiGene retained rights in China and other countries. Novartis terminated the partnership in 2023 citing a 'changing PD-1 landscape' and returned all rights to BeiGene. BeiGene subsequently self-launched tislelizumab globally as Tevimbra, winning successive FDA approvals it now holds outright: second-line ESCC (March 2024), first-line HER2-negative gastric/GEJ adenocarcinoma (December 2024), and first-line PD-L1-positive ESCC (2025), alongside earlier EU approvals. In May 2025 the former counterparty renamed itself BeOne Medicines Ltd. and redomiciled to Switzerland. The termination thesis has held: the asset Novartis walked away from has continued a successful independent global launch.
236K US cases/yr · $35.0B Global NSCLC Market (2024)
NSCLC is the most common form of lung cancer with a large and growing treatment market dominated by PD-1/PD-L1 checkpoint inhibitors. Tislelizumab (Tevimbra) was BeiGenes PD-1 antibody licensed to Novartis for ex-China markets, but the deal was terminated in 2023 as the PD-1 landscape became overcrowded.
The PD-1/PD-L1 class includes Keytruda, Opdivo, Tecentriq, Imfinzi, and Libtayo among others. Tislelizumab gained EU approval for ESCC but Novartis concluded the commercial opportunity was insufficient to justify continued investment, returning all rights to BeiGene.
229K US cases/yr · $33.0B Global anti-PD-(L)1 market 2021 (USD MM) · 135720 US lung cancer deaths annually
Tislelizumab targeted three high-incidence solid tumor indications at deal date. Non-small cell lung cancer (NSCLC) accounted for ~85% of US lung cancer cases (~228,820 new lung cancer cases and ~135,720 lung cancer deaths annually per ACS 2020), with first-line metastatic NSCLC therapy dominated by anti-PD-1/L1 monotherapy or combinations (KEYNOTE-024, -189, -407, CheckMate 9LA, IMpower150, EMPOWER-Lung 1). Esophageal cancer represented ~18,440 new US cases and ~16,170 deaths annually, with esophageal squamous cell carcinoma (ESCC) accounting for >50% of cases globally and a higher share in Asian populations; first-line metastatic ESCC therapy at deal date was platinum-fluoropyrimidine chemo with checkpoint inhibition emerging post-KEYNOTE-590 and CheckMate 648. Hepatocellular carcinoma (HCC) accounted for ~42,810 new US cases annually with first-line systemic therapy moving from sorafenib/lenvatinib to atezolizumab + bevacizumab (IMbrave150) and tremelimumab + durvalumab (HIMALAYA). The 2021 global anti-PD-(L)1 market exceeded $33 billion, dominated by Merck Keytruda (pembrolizumab, $17.2B 2021 revenue), BMS Opdivo (nivolumab, $7.5B), Roche Tecentriq (atezolizumab, $3.1B), AstraZeneca Imfinzi (durvalumab, $2.4B) and Regeneron Libtayo (cemiplimab, $0.4B). The PD-1 class became commoditized with multiple Chinese-developed PD-1 antibodies (BeiGene tislelizumab, Innovent sintilimab, Junshi toripalimab, Hengrui camrelizumab) seeking ex-China commercialization partnerships with multinational pharma.
At deal date (Jan 2021), the global anti-PD-(L)1 monoclonal antibody class was the most crowded oncology category in development. Approved Western anti-PD-1 agents included Merck Keytruda (pembrolizumab, approved 2014), BMS Opdivo (nivolumab, approved 2014), Regeneron/Sanofi Libtayo (cemiplimab, approved 2018), GSK Jemperli (dostarlimab, approved Apr 2021). Approved anti-PD-L1 agents included Roche Tecentriq (atezolizumab, 2016), AstraZeneca Imfinzi (durvalumab, 2017), Pfizer/Merck KGaA Bavencio (avelumab, 2017). Approved anti-CTLA-4 ipilimumab (Yervoy, BMS 2011) and anti-LAG-3 relatlimab (Opdualag, BMS 2022, in development at deal date). Chinese-developed anti-PD-1 agents seeking global commercialization included BeiGene tislelizumab (NMPA approved Dec 2019, partnered with Novartis Jan 2021), Innovent Biologics sintilimab (Tyvyt, NMPA 2018, partnered with Lilly globally Aug 2015 → returned 2022 after FDA Adcom rejection March 2022), Junshi Biosciences toripalimab (Tuoyi, NMPA 2018, partnered with Coherus Feb 2021 → US FDA approval Loqtorzi Oct 2023), Jiangsu Hengrui Pharmaceuticals camrelizumab (Airuika, NMPA 2019, partnered with Elevation Oncology), CStone Pharmaceuticals sugemalimab (anti-PD-L1, partnered with EQRx Oct 2020) and Akeso/Sino Biopharm penpulimab. Tislelizumab was differentiated by Fc-engineered IgG4 designed to minimize FcγR binding on macrophages and reduce antibody-dependent T-cell phagocytosis. Novartis terminated the tislelizumab collaboration in 2023 citing 'changing PD-1 landscape,' returned all rights, and BeiGene self-launched Tevimbra in EU (Sep 2023) and US (Mar 2024).
Novartis obtained ex-China development and commercialization rights to tislelizumab, BeiGene's anti-PD-1 monoclonal antibody, for $650 million upfront plus up to $1.55 billion in regulatory and sales milestones. BeiGene retained rights in China and other countries. Novartis termi
Post-termination, BeiGene won FDA approval for Tevimbra (tislelizumab-jsgr) plus chemotherapy in first-line HER2-negative, PD-L1-positive gastric/GEJ adenocarcinoma (RATIONALE-305), expanding the US label of the asset Novartis returned in 2023. Reinforces the termination thesis: BeiGene is self-launching successfully ex-China.
Former licensor-counterparty BeiGene, Ltd. completed redomiciliation from the Cayman Islands to Switzerland and renamed to BeOne Medicines Ltd., effective May 27, 2025 (shareholder approval April 28, 2025). Same SEC CIK 0001651308; trading unaffected. Corporate-identity change only; does not alter the deal record.
Transaction terminated. countries. Novartis terminated the partnership in 2023 citing a 'changing PD-1 landscape' and returned all rights to BeiGene. BeiGene subsequently self-launched tislelizu
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / BeiGene Ltd. (this deal) | 2021 | $2.2B | 40 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2021 deals · Novartis AG deals · Oncology deals